Back

Sacubitril/ valsartan in patients with congenital heart disease: a systematic review and meta-analysis

31 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Adult congenital heart disease: medical treatment Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Despoina Ntiloudi

Tzaneio General Hospital of Piraeus, Pireas (Greece)

8 More presentations in this session

Presentation thumbnail
Dapagliflozin prevents fibrogenic activation in endocardial endothelial cells under altered flow
Ms J. Gaal (Boston, US) Doctor I. Friehs (Boston, US)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter 2 inhibitors for the treatment of single ventricle circulatory failure in adults with congenital heart disease
Doctor R. Neijenhuis (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Results of CHASM IN ACHD (peer CoacHing Adaptive Self-Management INterventions for young Adults with Congenital Heart Disease) study
Doctor R. Krasuski (Durham, US)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter-2 inhibitor use in children with left ventricular systolic dysfunction: a matched case-control analysis
Doctor D. Newland (Seattle, US)
Abstract Slides Video
Presentation thumbnail
Impact on adverse events of guideline-directed medical therapy for heart failure in patients with a systemic right ventricle
Doctor I. Altobelli (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Adult congenital heart disease: medical treatment

The Event

Event poster

ESC Congress 2025

31 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
A meta-analysis of the effects of sacubitril-valsartan on surrogate markers of systemic right ventricular dysfunction in congenital heart disease
thumbnail
Congress Presentation
Coronary artery disease in adults with congenital heart disease: a systematic review and meta-analysis
thumbnail
Congress Presentation
Angiotensin receptor-neprilysin inhibitor-based therapy among adult heart failure patients with below normal systemic ventricular ejection fraction and complex congenital heart disease